Biogen to collaborate with NeuroSense on ALS trial

Israel-based NeuroSense Therapeutics (Nasdaq: NRSN) announced in a Securities and Exchange Commission that it has entered into a collaborative evaluation agreement with a unit of US biotech major Biogen (Nasdaq: BIIB). NeuroSense share gained more than 6% to $1.90 in pre-market trading on the new.

The deal will see Biogen evaluate the impact of PrimeC on neurofilament levels in the plasma of participants in PARADIGM, NeuroSense’s Phase IIb clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). Biogen will fund the neurofilament biomarker study and conduct the analysis.

Biogen recently has its own success in the ALS space, gaining US regulatory approval for its Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).